We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Results Confirm Effectiveness of Echotherapy for Breast Fibroadenoma

By HospiMedica International staff writers
Posted on 21 Jun 2016
A French therapeutic ultrasound company has announced the results of a German trial of its ecotherapy technology that have confirmed its effectiveness in the destruction of Breast FibroAdenoma nodules.

The results of the Breast FibroAdenoma (BFA) trial in which 27 patients were enrolled, were presented at the German Congress of Senology in Dresden, Germany, at the end of May 2016. More...
The aim of the study was to evaluate the safety and efficacy of the new technique.

The trial took place at Tübingen University (Tübingen, Germany). The researchers used therapeutic ultrasound technology developed by Theraclion (Malakoff, France).

Biopsies were performed 12 months after the ecotherapy procedure and showed that nearly 24 of the 27 patients (nearly 90%) had no residual vital BFA tissue. All the patients except for one were prepared to recommend the procedure. The original aim of the non-invasive BFA treatment was to reduce the volume of BFAs, however the new trial confirmed that complete tissue destruction was also possible. The procedure does not using ionizing radiation, and could be used to treat breast cancer patients in the near future.

CMO of Theraclion, Michel Nuta, said, “These results are extremely encouraging. Echotherapy has initially been designed for volume reduction of a nodule, not for its complete destruction. These preliminary results show that there is reason to believe that by adapting the protocol, complete tissue destruction can be obtained.”

Related Links:
Tübingen University
Theraclion

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.